Francisco J. Esteva: The evolution of HER2 as a pivotal biomarker in breast cancer diagnosis and treatment is a fascinating story

Francisco J. Esteva, Chief of Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared on LinkedIn:

“The evolution of HER2 as a pivotal biomarker in breast cancer diagnosis and treatment is a fascinating story. From its discovery in the 1980s to the groundbreaking advancements in therapy, in this podcast I discuss the nuances of HER2 positive, negative, and the newly recognized HER2-Low category.

As we navigate the complexities of breast cancer, it is important to recognize how targeted therapies such as trastuzumab deruxtecan have transformed patient prognoses from the worst to some of the best outcomes in oncology.”

Proceed to video.
Source: Francisco J. Esteva/LinkedIn